Showing results (21-30 of 148) with videos related to
Sort By:
Pageof 15
Journal of Immunology (Baltimore, Md. : 1950)|October 18, 2015
A Complement-Optimized EGFR Antibody Improves Cytotoxic Functions of Polymorphonuclear Cells against Tumor CellsStefanie Derer, Michael Cossham, Thies Rösner, et al.Haematologica|June 6, 2020
Fc-engineering significantly improves the recruitment of immune effector cells by anti-ICAM-1 antibody MSH-TP15 for myeloma therapyKatja Klausz, Michael Cieker, Christian Kellner, et al.Cancer Letters|February 23, 2011
Heterodimeric bispecific antibody-derivatives against CD19 and CD16 induce effective antibody-dependent cellular cytotoxicity against B-lymphoid tumor cellsChristian Kellner, Joerg Bruenke, Heike Horner, et al.Mabs|January 14, 2010
Sensitivity and resistance to EGF-R inhibitors: approaches to enhance the efficacy of EGF-R antibodiesMatthias Peipp, Michael Dechant, Thomas ValeriusMolecular Cancer Therapeutics|November 2, 2021
The Novel Dual Topoisomerase Inhibitor P8-D6 Shows Anti-myeloma Activity In Vitro and In VivoKatja Klausz, Christian Kellner, Carina Lynn Gehlert, et al.Methods in Molecular Biology (Clifton, N.J.)|May 13, 2026
Combination of Fc-Protein Engineering Strategies: Design and Evaluation of Antibody Effector FunctionsCarina Lynn Gehlert, Steffen Krohn, Dorothee Winterberg, et al.Current Opinion in Immunology|July 1, 2008
Effector mechanisms of therapeutic antibodies against ErbB receptorsMatthias Peipp, Michael Dechant, Thomas ValeriusMethods in Molecular Biology (Clifton, N.J.)|July 5, 2023
Identification of New Antibodies Targeting Tumor Cell Surface Antigens by Phage DisplaySteffen Krohn, Matthias Peipp, Katja KlauszJournal of Immunotherapy (Hagerstown, Md. : 1997)|October 4, 2008
A novel CD19-directed recombinant bispecific antibody derivative with enhanced immune effector functions for human leukemic cellsChristian Kellner, Joerg Bruenke, Julia Stieglmaier, et al.Transfusion Medicine and Hemotherapy : Offizielles Organ Der Deutschen Gesellschaft Fur Transfusionsmedizin Und Immunhamatologie|October 27, 2017
An Fc Double-Engineered CD20 Antibody with Enhanced Ability to Trigger Complement-Dependent Cytotoxicity and Antibody-Dependent Cell-Mediated CytotoxicityTim Wirt, Sophia Rosskopf, Thies Rösner, et al.Pageof 15